Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from HC Wainwright

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $18.00 price target on the stock. HC Wainwright’s price target suggests a potential upside of 219.72% from the stock’s previous close.

A number of other equities analysts also recently commented on COYA. Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Chardan Capital reaffirmed a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a report on Tuesday, May 13th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Tuesday, April 22nd. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.

Coya Therapeutics Price Performance

COYA opened at $5.63 on Monday. Coya Therapeutics has a fifty-two week low of $4.65 and a fifty-two week high of $10.24. The business has a 50-day moving average of $5.77 and a 200-day moving average of $6.05. The company has a market capitalization of $94.16 million, a PE ratio of -8.66 and a beta of 0.22.

Coya Therapeutics (NASDAQ:COYA) last posted its earnings results on Tuesday, May 13th. The company reported ($0.44) EPS for the quarter, hitting the consensus estimate of ($0.44). The business had revenue of $257.88 million during the quarter, compared to the consensus estimate of $2.63 million. On average, equities research analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Trading of Coya Therapeutics

Institutional investors have recently made changes to their positions in the business. Northern Trust Corp raised its position in Coya Therapeutics by 12.2% during the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after acquiring an additional 3,099 shares in the last quarter. Tower Research Capital LLC TRC raised its position in shares of Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after purchasing an additional 4,777 shares during the period. Geode Capital Management LLC raised its position in shares of Coya Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock valued at $863,000 after purchasing an additional 8,267 shares during the period. Charles Schwab Investment Management Inc. bought a new position in shares of Coya Therapeutics in the first quarter valued at about $65,000. Finally, XTX Topco Ltd bought a new position in shares of Coya Therapeutics in the fourth quarter valued at about $59,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.